Compare Stocks: KRRO, BBOT, IRWD, and STTK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBOT BridgeBio Oncology Therapeutics	$8.98 +0.9%	$8.74	$7.00 ▼ $14.87	$713.55M	0.38	258,116 shs	117,619 shs
IRWD Ironwood Pharmaceuticals	$4.26 -0.7%	$4.18	$1.05 ▼ $5.78	$708.88M	0.2	1.73 million shs	829,289 shs
KRRO Korro Bio	$12.24 +5.3%	$12.67	$5.20 ▼ $55.89	$171.12M	3.09	79,148 shs	78,429 shs
STTK Shattuck Labs	$6.79 -2.4%	$7.16	$1.45 ▼ $8.33	$698.53M	1.09	813,475 shs	677,731 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBOT BridgeBio Oncology Therapeutics	+0.90%	+2.75%	+0.22%	+14.98%	+897,999,900.00%
IRWD Ironwood Pharmaceuticals	-0.70%	+3.15%	+2.65%	+28.70%	+243.55%
KRRO Korro Bio	+5.34%	-5.19%	+6.43%	+14.18%	-52.98%
STTK Shattuck Labs	-2.44%	-3.55%	-7.87%	+48.25%	+430.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBOT BridgeBio Oncology Therapeutics	$8.98 +0.9%	$8.74	$7.00 ▼ $14.87	$713.55M	0.38	258,116 shs	117,619 shs
IRWD Ironwood Pharmaceuticals	$4.26 -0.7%	$4.18	$1.05 ▼ $5.78	$708.88M	0.2	1.73 million shs	829,289 shs
KRRO Korro Bio	$12.24 +5.3%	$12.67	$5.20 ▼ $55.89	$171.12M	3.09	79,148 shs	78,429 shs
STTK Shattuck Labs	$6.79 -2.4%	$7.16	$1.45 ▼ $8.33	$698.53M	1.09	813,475 shs	677,731 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBOT BridgeBio Oncology Therapeutics	+0.90%	+2.75%	+0.22%	+14.98%	+897,999,900.00%
IRWD Ironwood Pharmaceuticals	-0.70%	+3.15%	+2.65%	+28.70%	+243.55%
KRRO Korro Bio	+5.34%	-5.19%	+6.43%	+14.18%	-52.98%
STTK Shattuck Labs	-2.44%	-3.55%	-7.87%	+48.25%	+430.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBOT BridgeBio Oncology Therapeutics	2.75	Moderate Buy	$24.40	171.71% Upside
IRWD Ironwood Pharmaceuticals	2.57	Moderate Buy	$6.23	46.32% Upside
KRRO Korro Bio	2.92	Moderate Buy	$16.71	36.55% Upside
STTK Shattuck Labs	3.00	Buy	$12.78	88.19% Upside

Current Analyst Ratings Breakdown

Latest KRRO, BBOT, IRWD, and STTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C+)
8/20/2026	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
8/14/2026	BBOT BridgeBio Oncology Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$27.00 ➝ $25.00
8/11/2026	STTK Shattuck Labs	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$18.00 ➝ $14.00
8/7/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/30/2026	IRWD Ironwood Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/24/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
7/24/2026	STTK Shattuck Labs	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	$4.03 per share	N/A
IRWD Ironwood Pharmaceuticals	$296.15M	2.38	$0.26 per share	16.67	($0.98) per share	-4.35
KRRO Korro Bio	$2.38M	75.67	N/A	N/A	$7.01 per share	1.75
STTK Shattuck Labs	$1M	681.44	N/A	N/A	$2.10 per share	3.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBOT BridgeBio Oncology Therapeutics	-$134.04M	-$2.76	N/A	N/A	N/A	N/A	-46.90%	-42.17%	N/A
IRWD Ironwood Pharmaceuticals	$24.02M	$0.77	5.53	N/A	N/A	33.36%	-58.38%	34.93%	11/9/2026 (Estimated)
KRRO Korro Bio	-$117.26M	-$10.00	N/A	N/A	N/A	-1,834.48%	-114.26%	-68.57%	11/11/2026 (Estimated)
STTK Shattuck Labs	-$48.81M	-$0.51	N/A	N/A	N/A	N/A	-43.57%	-40.90%	11/10/2026 (Estimated)

Latest KRRO, BBOT, IRWD, and STTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	BBOT BridgeBio Oncology Therapeutics	N/A	-$705.20	N/A	-$705.20	N/A	N/A
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A
8/6/2026	Q2 2026	IRWD Ironwood Pharmaceuticals	$0.32	$0.31	-$0.01	$0.31	$114.84 million	$113.04 million
8/6/2026	Q2 2026	KRRO Korro Bio	-$1.34	-$1.07	+$0.27	-$1.07	$0.21 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBOT BridgeBio Oncology Therapeutics	N/A	4.69	4.69
IRWD Ironwood Pharmaceuticals	N/A	6.06	6.06
KRRO Korro Bio	N/A	9.55	9.55
STTK Shattuck Labs	N/A	27.59	27.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBOT BridgeBio Oncology Therapeutics	54.89%
IRWD Ironwood Pharmaceuticals	N/A
KRRO Korro Bio	13.18%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
BBOT BridgeBio Oncology Therapeutics	24.40%
IRWD Ironwood Pharmaceuticals	9.30%
KRRO Korro Bio	4.80%
STTK Shattuck Labs	8.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBOT BridgeBio Oncology Therapeutics	N/A	80.17 million	60.61 million	N/A
IRWD Ironwood Pharmaceuticals	220	165.24 million	149.87 million	Optionable
KRRO Korro Bio	70	14.73 million	14.02 million	No Data
STTK Shattuck Labs	100	100.36 million	91.54 million	Optionable

KRRO, BBOT, IRWD, and STTK Headlines

Recent News About These Companies

Shattuck Labs, Inc. (NASDAQ:STTK) Given Consensus Recommendation of "Buy" by Analysts

1 hour ago | americanbankingnews.com

The Manufacturers Life Insurance Company Invests $1.58 Million in Shattuck Labs, Inc. $STTK

September 4 at 4:31 AM | marketbeat.com

BlackRock Inc. Invests $27.32 Million in Shattuck Labs, Inc. $STTK

September 3 at 3:43 AM | marketbeat.com

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

September 2 at 4:05 PM | globenewswire.com

Shattuck Labs: A Receptor-Side Bet On The TL1A Boom

September 1, 2026 | seekingalpha.com

Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Recommendation of "Buy" from Brokerages

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Invests $1.99 Million in Shattuck Labs, Inc. $STTK

August 30, 2026 | marketbeat.com

356,528 Shares in Shattuck Labs, Inc. $STTK Bought by Deutsche Bank AG

August 28, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Upgraded at TD Cowen

August 27, 2026 | americanbankingnews.com

Raymond James Financial Upgrades Shattuck Labs (NASDAQ:STTK) to "Strong-Buy"

August 26, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Stock Rating Upgraded by TD Cowen

August 25, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Stock Price Up 5.5% - Here's What Happened

August 24, 2026 | marketbeat.com

S&G Foundation Makes New $3.02 Million Investment in Shattuck Labs, Inc. $STTK

August 23, 2026 | marketbeat.com

Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?

August 20, 2026 | zacks.com

Shattuck Labs (NASDAQ:STTK) Cut to Hold at Wall Street Zen

August 15, 2026 | marketbeat.com

Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade

August 13, 2026 | zacks.com

Q3 EPS Estimates for Shattuck Labs Raised by HC Wainwright

August 13, 2026 | marketbeat.com

Shattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value Milestone

August 12, 2026 | tipranks.com

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 11, 2026 | markets.businessinsider.com

Shattuck Labs Releases Q2 2026 10-Q Filing Highlighting Key Risk Factors and Share Count

August 11, 2026 | kalkinemedia.comK

HC Wainwright Cuts Shattuck Labs (NASDAQ:STTK) Price Target to $14.00

August 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO, BBOT, IRWD, and STTK Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

$8.98 +0.08 (+0.90%)

As of 09/4/2026 04:00 PM Eastern

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.

Ironwood Pharmaceuticals NASDAQ:IRWD

$4.26 -0.03 (-0.70%)

As of 09/4/2026 04:00 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Korro Bio NASDAQ:KRRO

$12.24 +0.62 (+5.34%)

As of 09/4/2026 04:00 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Shattuck Labs NASDAQ:STTK

$6.79 -0.17 (-2.44%)

As of 09/4/2026 04:00 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KRRO, BBOT, IRWD, and STTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KRRO, BBOT, IRWD, and STTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KRRO, BBOT, IRWD, and STTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO, BBOT, IRWD, and STTK Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Ironwood Pharmaceuticals NASDAQ:IRWD

Korro Bio NASDAQ:KRRO

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KRRO, BBOT, IRWD, and STTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KRRO, BBOT, IRWD, and STTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KRRO, BBOT, IRWD, and STTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO, BBOT, IRWD, and STTK Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Ironwood Pharmaceuticals NASDAQ:IRWD

Korro Bio NASDAQ:KRRO

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools